AbbVie’s Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.

Sanofi’s neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart in rare disease CIDP was stopped for futility.

May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie’s Skyrizi and RInvoq, Johnson & Johnson’s

Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.

EVERSANA has named Jen Norton as president of its recently formed Market Access & Value division.